<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573036</url>
  </required_header>
  <id_info>
    <org_study_id>HRS4800-I-101-AUS</org_study_id>
    <nct_id>NCT04573036</nct_id>
  </id_info>
  <brief_title>A Trial of HRS4800 Tables in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food on the Pharmacokinetics of HRS4800 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site study to evaluate the safety, tolerability and pharmacokinetics (PK) of&#xD;
      single dose administration of HRS4800, and the effect of food on the PK of HRS4800 in healthy&#xD;
      male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of AEs</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in diastolic blood pressure and systolic blood pressure from baseline</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pulse rate from baseline</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate from baseline</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QT interval from baseline by ECG</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in corrected QT (QTc) interval from baseline by ECG</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in P-R interval from baseline by ECG</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>HRS4800 tablets cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HRS4800 tablets cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HRS4800 tablets cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HRS4800 tablets cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HRS4800 tablets cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS4800 tablets</intervention_name>
    <description>single oral administration</description>
    <arm_group_label>HRS4800 tablets cohort 1</arm_group_label>
    <arm_group_label>HRS4800 tablets cohort 2</arm_group_label>
    <arm_group_label>HRS4800 tablets cohort 3</arm_group_label>
    <arm_group_label>HRS4800 tablets cohort 4</arm_group_label>
    <arm_group_label>HRS4800 tablets cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>single oral administration</description>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the purposes and risks of the trial and comply with all study&#xD;
             procedures before entering the trial, and provide signed informed consent.&#xD;
&#xD;
          -  Male aged between 18 years and 55 years at screening, inclusive.&#xD;
&#xD;
          -  Total body weight â‰¥50 kg at screening, and body mass index (BMI) between 18.0 and 32.0&#xD;
             kg/m2, inclusive.&#xD;
&#xD;
          -  Agree to practice true abstinence; be surgically sterilised (performed at least 6&#xD;
             months prior and documented to no longer produce sperm - verbal confirmation through&#xD;
             medical history review acceptable); or agree to use a condom if sexually active with a&#xD;
             female partner of childbearing potential for at least 3 months after dosing.&#xD;
&#xD;
          -  No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry,&#xD;
             coagulation function), and ECG, as determined by the investigator. Male aged between&#xD;
             18 years and 55 years at screening, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe digestive system disease or having a digestive disease currently&#xD;
             within a month of screening or before first dosing, and may affect drug absorption or&#xD;
             have safety risks.&#xD;
&#xD;
          -  Severe infections, injuries or surgeries within 3 months of screening or before first&#xD;
             dosing, or plan to undergo any surgeries during the trial.&#xD;
&#xD;
          -  Use of any medicine affecting liver metabolism within 1 month of screening (see&#xD;
             Appendix 1); use of any prescription medications within 14 days or 5 half-lives prior&#xD;
             to dosing, use of any over-the-counter medicine or herbal products within 7 days prior&#xD;
             to dosing; intention to use any other medicine during the trial.&#xD;
&#xD;
          -  Whole blood donation or loss of more than 200 mL of blood within 1 month prior to&#xD;
             dosing; or blood donation or loss of more than 400 mL of blood within 3 months prior&#xD;
             to dosing; or plasma donation within 14 days prior to dosing; or received blood within&#xD;
             8 weeks prior to dosing.&#xD;
&#xD;
          -  History of allergy to the study drug or any component of it.&#xD;
&#xD;
          -  History of regular alcohol consumption in the past 1 month exceeding an average weekly&#xD;
             intake of 21 standard drinks: 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL]&#xD;
             of beer or 1.5 ounces [45 mL] of hard liquor).&#xD;
&#xD;
          -  Subject has used more than 5 tobacco or nicotine-containing products per day in the 6&#xD;
             months prior to dosing and is unable to refrain from use of such products from at&#xD;
             least 48 hours prior to check-in through to the final study visit.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days (or 5 half-lives, whichever is&#xD;
             longer) of dosing.&#xD;
&#xD;
          -  History of drug abuse within 2 years prior to screening.&#xD;
&#xD;
          -  Other conditions or laboratory abnormality that may increase the risk associated with&#xD;
             study participation or IP administration or interfere with the interpretation of study&#xD;
             results and, at the discretion of the investigator, makes the subject inappropriate&#xD;
             for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schrader</last_name>
      <phone>0863825100</phone>
      <email>pschrader@linear.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

